Alto Neuroscience, Inc. (ANRO) stock
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
$27.12−2.42 (-8.19%)
Close on Nov 16, 2026Market cap $1.06BP/E –Yield –
Alto Neuroscience total assets
Total assets on the balance sheet at the end of each period.
Alto Neuroscience's total assets was $326.51M at Sep 30, 2026. For fiscal 2025 it was $184.69M, up 4.0% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.69M | +4.0% |
| FY2024 | Dec 31, 2024 | $177.54M | +104.9% |
| FY2023 | Dec 31, 2023 | $86.63M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $326.51M | +122.1% |
| Q2 FY2026 | Jun 30, 2026 | $254.07M | +60.9% |
| Q1 FY2026 | Mar 31, 2026 | $276.26M | +60.7% |
| Q4 FY2025 | Dec 31, 2025 | $184.69M | +4.0% |
| Q3 FY2025 | Sep 30, 2025 | $147.01M | -23.3% |
| Q2 FY2025 | Jun 30, 2025 | $157.88M | -20.0% |
| Q1 FY2025 | Mar 31, 2025 | $171.92M | -18.1% |
| Q4 FY2024 | Dec 31, 2024 | $177.54M | +104.9% |
| Q3 FY2024 | Sep 30, 2024 | $191.61M | – |
| Q2 FY2024 | Jun 30, 2024 | $197.36M | – |
| Q1 FY2024 | Mar 31, 2024 | $209.92M | – |
| Q4 FY2023 | Dec 31, 2023 | $86.63M | – |
See a number that looks wrong?